Migraine Disorders

"Migraine Disorders" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A class of disabling primary headache disorders, characterized by recurrent unilateral pulsatile headaches. The two major subtypes are common migraine (without aura) and classic migraine (with aura or neurological symptoms). (International Classification of Headache Disorders, 2nd ed. Cephalalgia 2004: suppl 1)

Descriptor ID	D008881
MeSH Number(s)	C10.228.140.546.399.750
Concept/Terms	Migraine Disorders Migraine Disorders Disorder, Migraine Disorders, Migraine Migraine Disorder Migraine Migraines Migraine Headache Headache, Migraine Headaches, Migraine Migraine Headaches Acute Confusional Migraine Acute Confusional Migraine Acute Confusional Migraines Migraine, Acute Confusional Migraines, Acute Confusional Status Migrainosus Status Migrainosus Hemicrania Migraine Hemicrania Migraine Hemicrania Migraines Migraine, Hemicrania Migraines, Hemicrania Migraine Variant Migraine Variant Migraine Variants Variant, Migraine Variants, Migraine Sick Headache Sick Headache Headache, Sick Headaches, Sick Sick Headaches Abdominal Migraine Abdominal Migraine Abdominal Migraines Migraine, Abdominal Migraines, Abdominal Cervical Migraine Syndrome Cervical Migraine Syndrome Cervical Migraine Syndromes Migraine Syndrome, Cervical Migraine Syndromes, Cervical

Below are MeSH descriptors whose meaning is more general than "Migraine Disorders".

Diseases [C]
Nervous System Diseases [C10]
Central Nervous System Diseases [C10.228]
Brain Diseases [C10.228.140]
Headache Disorders [C10.228.140.546]
Headache Disorders, Primary [C10.228.140.546.399]
Migraine Disorders [C10.228.140.546.399.750]

Below are MeSH descriptors whose meaning is related to "Migraine Disorders".

Below are MeSH descriptors whose meaning is more specific than "Migraine Disorders".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Migraine Disorders" by people in this website by year, and whether "Migraine Disorders" was a major or minor topic of these publications.

Bar chart showing 868 publications over 30 distinct years, with a maximum of 55 publications in 2019

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	5	0	5
1997	9	0	9
1998	9	1	10
1999	10	1	11
2000	14	2	16
2001	18	1	19
2002	29	1	30
2003	25	3	28
2004	39	3	42
2005	31	2	33
2006	30	3	33
2007	38	2	40
2008	33	4	37
2009	32	4	36
2010	29	3	32
2011	17	2	19
2012	25	2	27
2013	27	2	29
2014	29	0	29
2015	24	4	28
2016	22	0	22
2017	22	2	24
2018	43	0	43
2019	54	1	55
2020	45	2	47
2021	52	0	52
2022	40	0	40
2023	32	0	32
2024	35	1	36
2025	4	0	4

Below are the most recent publications written about "Migraine Disorders" by people in Profiles.

Qaseem A, Cooney TG, Etxeandia-Ikobaltzeta I, Wilt TJ, Harrod CS, Tice JA, Crandall CJ, Hicks LA, Cross JT, Fitterman N, Lewis J, Linsky AM, Maroto M, Miller MC, Obley AJ, Owens DK, Shekelle PG, Shamliyan T, Yost J. Prevention of Episodic Migraine Headache Using Pharmacologic Treatments in Outpatient Settings: A Clinical Guideline From the American College of Physicians. Ann Intern Med. 2025 Mar; 178(3):426-433.

View in: PubMed
Guzman G, Kopruszinski CM, Barber KR, Lillo Vizin RC, Dodick DW, Navratilova E, Porreca F. Chronification of migraine sensitizes to CGRP in male and female mice. Cephalalgia. 2025 Feb; 45(2):3331024251317446.

View in: PubMed
Tepper SJ, Tepper K. Nutraceuticals and Headache 2024: Riboflavin, Coenzyme Q10, Feverfew, Magnesium, Melatonin, and Butterbur. Curr Pain Headache Rep. 2025 Jan 24; 29(1):33.

View in: PubMed
Lee GJ, Hode V, Georgieva T, Rau J, Dodick DW, Schwedt TJ, Neugebauer V, Porreca F, Navratilova E. Prolactin-induced sensitization of trigeminal nociceptors promotes migraine co-morbidity in endometriosis. Cephalalgia. 2025 Jan; 45(1):3331024241313378.

View in: PubMed
Tepper SJ, Diamond ML, Hirman J, Asher D, Fiore D, Cady R. Eptinezumab treatment was associated with longer interictal headache/migraine periods which corresponded to greater improvements in patient-reported quality of life measures. J Neurol. 2024 Dec 12; 272(1):4.

View in: PubMed
Peterlin BL, Bond DS, Ailani J, Dodick DW, Liu Y, De Abreu Ferreira R, Smith JH, Dabruzzo B, Goadsby PJ, Trugman JM. Weight loss with atogepant during the preventive treatment of migraine: A pooled analysis. Cephalalgia. 2024 Dec; 44(12):3331024241299753.

View in: PubMed
Ailani J, Lipton RB, Blumenfeld AM, Mechtler L, Klein BC, He MY, Smith JH, Trugman JM, de Abreu Ferreira R, Brand-Schieber E. Safety and tolerability of ubrogepant for the acute treatment of migraine in participants taking atogepant for the preventive treatment of episodic migraine: Results from the TANDEM study. Headache. 2025 Jun; 65(6):1005-1014.

View in: PubMed
de Oliveira AB, Peres MFP, Mercante JPP, Brunoni AR, Wang YP, Molina MDCB, Uchiyama LK, Lotufo PA, Bense?or IM, Goulart AC. Associations of comorbid headache disorders and depression with leisure-time physical activity among 14,088 adults in The Brazilian Longitudinal Study of Adult Health. Headache. 2025 Apr; 65(4):643-654.

View in: PubMed
Tepper SJ, Albrecht D, Ailani J, Kirby L, Strom S, Rapoport AM. Long-Term (12-Month) Safety and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine: Data from the Phase 3 Open-Label ASCEND Study. CNS Drugs. 2024 Dec; 38(12):1017-1027.

View in: PubMed
Ailani J, Gandhi P, Lalla A, Halker Singh R, McAllister P, Smith JH, Dabruzzo B, Chalermpalanupap N, Kelton K, Nahas SJ. Cost per treatment responder analysis of atogepant compared to rimegepant for the preventive treatment of episodic migraine. Headache. 2024 Nov-Dec; 64(10):1253-1263.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement